Contemporary Approach to Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.
Angela C HirbeCarina A DehnerEva DombiVanessa EuloAndrea M GrossTaylor SundbyAlexander J LazarBrigitte C WidemannPublished in: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting (2024)
Most malignant peripheral nerve sheath tumors (MPNSTs) are clinically aggressive high-grade sarcomas, arising in individuals with neurofibromatosis type 1 (NF1) at a significantly elevated estimated lifetime frequency of 8%-13%. In the setting of NF1, MPNSTs arise from malignant transformation of benign plexiform neurofibroma and borderline atypical neurofibromas. Composed of neoplastic cells from the Schwannian lineage, these cancers recur in approximately 50% of individuals, and most patients die within five years of diagnosis, despite surgical resection, radiation, and chemotherapy. Treatment for metastatic disease is limited to cytotoxic chemotherapy and investigational clinical trials. In this article, we review the pathophysiology of this aggressive cancer and current approaches to surveillance and treatment.
Keyphrases
- peripheral nerve
- high grade
- clinical trial
- signaling pathway
- end stage renal disease
- squamous cell carcinoma
- small cell lung cancer
- lps induced
- oxidative stress
- ejection fraction
- locally advanced
- chronic kidney disease
- nuclear factor
- papillary thyroid
- randomized controlled trial
- peritoneal dialysis
- prognostic factors
- phase ii
- inflammatory response
- combination therapy
- smoking cessation
- cell fate